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Abstract 
Among the drug delivery strategies intended to increase the 
bioavailability of drugs, the use of polymeric biodegradable 
microcarriers has shown a significant degree of success. 
The purpose of this study was developing a polymeric drug delivery 
system for a model drug: furosemide, which belongs to class IV of BCS 
(low solubility and low permeability), intended to oral administration 
and improving the stability and intestinal absorption of the drug.  
To achieve this goal, furosemide loaded poly (lactic-co-glycolic acid) 
(PLGA) microparticles were prepared by solvent evaporation method 
and characterized. To obtain an appropriate mathematical model with 
minimum experiments for optimization of formulation, a 24 full factorial 
design based on four independent variables (amount of polymer, 
emulsifier, volume of internal and external phases) was used to plan the 
experiments. The effects of these parameters on the drug loading 
efficiency were investigated. The release profiles of furosemide from 
microparticles were examined in simulated gastric fluid (SGF pH 1.2), 
simulated intestinal fluid (SIF pH 7.4) and phosphate buffer (pH: 7.4). 
The results of optimized formulation showed a narrow size distribution 
with an average diameter of 60 ± 5 µm and a drug loading of more than 
60%. In simulated gastric fluid (SGF), less than 8% of furosemide was 
released from microparticles in 24 h and about 60% and 50% furosemide 
was released in 24 h in simulated intestinal fluid (SIF) and phosphate 
buffer, respectively. 
Results from this preliminary work showed that furosemide loaded 
PLGA microparticles can be successfully obtained through solvent-
evaporation technique, with good morphological characteristics, high 
encapsulation efficiency and controlled drug release profile suitable for 
per oral administration. 
Keywords: Furosemide; PLGA microparticles; Full factorial design. 
 
Introduction 
Furosemide, 5-(aminosulfonyl)-4-chloro-2-
[(furanylmethyl) amino] benzoic acid is a potent 
and short acting diuretic that widely used in the 
treatment of edematous states associated with 
cardiac chronic renal failure and hypertension 
[1,2].  
Although the therapeutic effect is fast and intense 
after oral administration of furosemide but it was 
previously reported its oral bioavailability was 
poor and shows erratic absorption and high 
intersubject variation in pharmacokinetic 
parameters [3]; however the causes of these 
problems remains unclear. Low solubility and 
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permeability, intestinal secretion by efflux pump; 
gastric elimination by acid hydrolysis may be 
causes of this problem [2-5].  
 
Among the recently drug delivery strategies 
intended to overcome this obstacle and increase 
the bioavailability of drugs, especially polymeric 
microparticles has shown a significant degree of 
success. 
 
Microparticles are one of the multiparticulate 
delivery systems and are prepared to obtain 
prolonged or controlled drug delivery, to improve 
bioavailability or stability and to target drug to 
specific sites. Microparticles can also offer 
advantages like limiting fluctuation within 
therapeutic range, reducing side effects, 
decreasing dosing frequency and improving 
patient compliance [6].  
 
The biodegradability or biocompatibility is an 
essential property for the polymer used for 
pharmaceutical applications. Among 
biodegradable polymers, poly (lactic-co-glycolic 
acid) (PLGA) has been studied for many years as 
a suitable drug delivery material; It can ultimately 
degrade by hydrolysis of their constituents, which 
are usual metabolic and non-toxic degradation 
products [7,8].  
 
Several methods were proposed for the 
preparation of PLGA microparticles, such as 
extrusion [9], spray drying [10] and supercritical 
fluid extraction [11]. The technique mostly used, 
however, is the emulsification solvent 
evaporation method. It involves the solution of 
the PLGA polymer in an organic solvent, 
emulsifying the PLGA solution in a non solvent 
(mostly water) and precipitating the PLGA 
polymer as particles by evaporating the organic 
solvent (Fig. 1) [12,13].  
 
Several important factors contribute to the 
effectiveness of solvent evaporation method in 
preparing particles with acceptable size range, 
shape and the percentage of the drug load, 
namely the amount of polymer, percentage of 
surfactant and volume of organic and aqueous 
phases. It is difficult to assess the effect of the 
variables individually or in combination, 
therefore deriving a mathematical model suitable 
for establishing a quantitative relationship 
between the formulation variables is necessary 
[14]. Factorial design is a very efficient tool to 
obtain an appropriate mathematical model with 
minimum experiments for optimization of 
formulation design. Studies based on factorial 
designs allow all the factors to be varied 
simultaneously, thus enabling evaluation of the 
effects of each variable at each level and showing 
inter relationship among them [15-22].  
 
 
Figure 1. 
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In this project a two-level factorial design 
experiment was used for obtaining a 
mathematical model and prediction of optimized 
formulations. The resulted furosemide 
microparticles were characterized with regard to 
morphology, size, drug loading, in vitro drug 
release and property in microspheres. 
 
Materials and methods  
Materials 
Furosemide was purchased from Auro 
Laboratories (India). poly (lactic-co-glycolic 
acid) (PLGA, 50:50 MW 12,000, inherent 
viscosity of 0.16–0.24 dl/g) was obtained from 
Boehringer Ingelheim Co. (Ingelheim, Germany) 
in the form of Resomer® 502H.  Polyvinyl 
alcohol (PVA, MW 130000 Da, 87% hydrolyzed) 
was purchased from Mowiol (Germany). 
Dichloromethane and dimethylformamide were 
purchased from Merck (Darmstadt, Germany). 
All other chemical reagents used were of 
pharmaceutical grade. All aqueous solutions were 
prepared exclusively in distilled water. 
 
Preparation of furosemide PLGA 
microparticles 
Furosemide loaded PLGA microparticles were 
prepared by o/w emulsion/solvent evaporation 
method. Procedure was as follows: exact quantity 
of PLGA polymer and furosemide (10 mg) was 
accurately weighted and dissolved in 
dichloromethane. The organic phase was added 
drop-wise (0.5 ml/min) into PVA aqueous 
solution and stirred magnetically at room 
temperature until complete evaporation of the 
organic solvent. Subsequently, microparticles 
were separated by centrifugation at 10000 rpm 
for 15 min. The separated microparticles were 
redispersed and centrifuged two times in 
phosphate buffer (PH: 7.4) and distilled water to 
completely remove free drug and excess 
surfactants. Microparticles were then collected 
and dried under room temperature. 
 
 
 
Experimental design 
A factorial design is frequently employed for the 
planning of a research because it provides the 
maximum of information, requiring the least 
experiments. A specific purpose of the 
experiments and a quantitative target function of 
the system are required to be accurately defined 
before experiments are designed. Most important 
variables which affect the system function are 
selected and systemic experiments are then 
performed to the specified factorial design. The 
number of independent variables selected decides 
the number of experiments that are to be 
performed. 
 
The response (Y) is measured for each 
experiment and then either a simple linear, 
interactive, or quadratic model is generated by 
carrying out multiple regression analysis and F-
Statistics to identify statistically significant terms. 
Responses Obtained from the reduced equation, 
an equation containing only statistically 
significant terms, are used for drawing response 
surface plots to visualize the impact of changing 
variables. The optimum point may be identified 
from the plot and replicate trials may be run to 
verify the prediction of optimum response [15-
22].  
 
Based on preliminary study of the effect of 
parameters on the drug loading of microsphere by 
solvent evaporation method, four different factors 
at two levels and their influence on the 
microparticles properties were evaluated using a 
2 4 Full factorial design. The four factors 
investigated were the amount of polymer, 
emulsifier percent and volume of internal and 
external phases. The different preparations were 
made in triplicate in order to estimate the 
experimental error. The design required a total of 
24 experiments with one replica each or mean of 
triplicate. For each factor, the lower and higher 
value of the lower and upper level can be 
represented by 1 or -1 sign. Values of these 
selected variables are shown in Table 1. 
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Characterization of furosemide microparticles 
Size measurement 
The particle size and size distribution of optimum 
PLGA microparticles were measured by the 
method of laser light diffraction using a particle 
size analyzer (Malvern, UK). The particle size 
was expressed as volume mean diameter in 
micrometers.  
 
Particle morphology 
The morphology of microparticles was 
determined using scanning electron microscopy 
(SEM) (Phillips, the Netherlands), the sample 
were prepared on aluminum stabs and coated 
with gold prior to examination by SEM. 
 
Differential scanning calorimetry (DSC) 
To verify the drug loaded property, the DSC of 
drug, PLGA polymer, physical mixture of drug 
with polymer and prepared microspheres. Five to 
ten milligrams of each sample was put in 
aluminum pans and hermetically sealed. The 
heating rate was 10˚C/min, nitrogen served as 
purge gas and the system were cooled down by 
liquid nitrogen. The DSC (DSC-60, Shimadzu 
Co. Kyoto, Japan) instrument was calibrated for 
temperature using octadecane and indium.  
 
Determination of drug loading and microparticle 
recovery 
 
Microparticles dried at room temperature were 
then weighed and the yield of microsphere 
preparation was calculated using the folowing 
equation 1: 
 
Equation 1: Microparticle recovery:  
Amount of microparticles obtained / amount of 
polymeric material and drug ×100 
 
The drug content in PLGA and the drug 
encapsulation efficiency (EE) were measured 
after extraction from the microparticles. 100 mg 
of drug-loaded microparticles was dissolved in 1 
mL of di-methyl formamide. The mixture was 
vortexed at 2500 rpm for 1 min and the solution 
was analyzed by UV/Vis spectrophotometer at a 
wavelength of 274 nm. Drug content was 
determined by comparing with a calibration curve 
of furosemide which had been prepared from 
DMF solutions with concentrations between 0.5- 
20 µg/mL.  
 
The drug loading efficiency (DLE) is expressed 
as follows equation 2: 
 
Equation 2: DLE: 
 Amount of furosemide in microparticles / amount 
of furosemide in formulation ×100 
 
In vitro drug release 
In vitro release studies were performed by 
dialysis method using Franz diffusion cell. The 
release media were simulated gastric fluid: SGF 
(pH 2.1), simulated intestinal fluid: SIF (pH 6.8) 
and phosphate buffer (pH 7.4). As regards to sink 
condition, 1ml of microparticle suspension in 
each of mediums was placed in donor site and 50 
ml desired medium in receptor chamber 
incubated at 37 ºC under magnetic stirring. At 
specific time intervals, 500µl of medium was 
taken and replaced with the same volume of fresh 
medium. The concentration of released 
furosemide was determined by UV analysis (λ: 
274 nm). The results were expressed as a 
percentage of the drug released as shown below 
equation 3: 
 
Equation 3: Drug released (%) 
Amount of furosemide released / amount of 
entrapment furosemide × 100 
 
 
Different mathematical models may be applied 
for describing the kinetics of the drug release 
process from microparticles, the most suited 
being the one which best fits the experimental 
results.  
 
The kinetics of furosemide release from PLGA 
microparticles were determined by finding the 
best fit of the release data to Higuchi and 
Korsmeyer-Peppas plots (23- 25). 
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Results and Discussion  
Factorial design 
The aim of the present investigation was to 
formulate and optimize process parameters for 
encapsulation of furosemide in PLGA 
microparticles based on a 24 statistical factorial 
design experiments 
 
A technique of two-level factorial design offers 
the possibility of investigating four independent 
variables at two levels after performing only 
sixteen experiments. The selection of factors and 
levels in the design, which most affects drug 
loading, would be based on the results of 
preliminary investigations. Primary independent 
factors that might affect drug loading in solvent-
evaporation method are: amount of polymer (A), 
percent of surfactant (B), volume of organic 
phase (C) and volume of aqueous phase (D). We 
evaluated the influence of these parameters on 
drug loading by a full factorial experimental 
design. Sixteen batches of different combinations 
were prepared by taking values of selected 
variables: A, B, C and D at two levels as shown 
in Table 1. 
 
 
Table 1:- Values and coded units of 2 4 factorial 
design for preparation of furosemide microparticles 
by solvent-evaporation method. 
 
Variables              Coded units                         Levels 
                                                               1                  2    
PLGA                                 A                     50               200   
PVA (%)                             B                     0.1              0.2   
Organic phase (ml)            C                      5                10   
Aqueous phase (ml)            D                      25               30   
 
To obtain a clearer view, the preparations of the 
factorial design can also be represented on cubes 
(Fig. 2), where the different axes represent the 
different variables. Because there are more 
factors than axes on a 3D-graph, the different 
samples can be represented on the corners of two 
cubes. 
 
 
Figure 2. 
 
Sixteen batches of microparticles were prepared 
according to experimental design shown in Table 
2 (four variables and one response of drug 
loading). Each batch was prepared three times 
and mean drug loading values were determined 
(Table 2). 
 
Table 2:- Experimental design and percentage of drug 
loading. 
Run 
PLGA 
mg 
PVA 
% 
 Int. 
Phase 
ml 
Ext.  
Phase 
ml 
Loading 
% 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
50 
50 
200 
200 
200 
200 
50 
200 
200 
50 
50 
200 
50 
50 
50 
200 
0.1 
0.2 
0.1 
0.2 
0.1 
0.1 
0.1 
0.2 
0.1 
0.2 
0.2 
0.2 
0.1 
0.2 
0.1 
0.2 
10 
10 
10 
5 
10 
5 
5 
10 
5 
5 
5 
5 
10 
10 
5 
10 
30 
25 
25 
30 
30 
30 
30 
25 
25 
25 
30 
25 
25 
30 
25 
30 
23±3.3 
28.6±5 
41.4±3 
37.7±4.3 
47±5 
60±5 
47.7±3.54
46.7±5 
48.3±4.23
41±3 
30±2 
59.3±5.5 
29.1±3.43
27±5 
37±2.5 
36±4 
 
 
 
The mathematical modelling of preparation of 
furosemide microcarriers was carried by the 
equation 4 in terms of coded factors: 
Equation 4:  
 
Loading = + 39.99 + 7.06×A – 1.70×B – 5.14×C 
+ 1.43×BC – 4.17×BD – 2.02×ABD + 
2.70×BCD 
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Where Y is dependent variable of drug loading. 
The result of analysis of variance (ANOVA) of 
the factorial design is presented in Table 3. 
Based on the results of ANOVA the Model F-
value of 27.06 implies the model is significant. 
There is only a 0.01% chance that a "Model F-
Value" this large could occur due to noise.Values 
of  "Prob > F" less than 0.0500 indicate model 
terms are significant.   In this case A, C, BD, 
ABD, BCD are significant model terms.   
 
The "Pred R-Squared" of 0.8379 is in reasonable 
agreement with the "Adj R-Squared" of 0.9240. 
"Adeq Precision" measures the signal to noise 
ratio.  A ratio greater than 4 is desirable.  Our 
ratio of 17.280 indicates an adequate signal.  This 
model can be used to navigate the design space. 
 
Polymer amount exhibited positive effect on the 
drug loading of microparticles. A high drug 
loading obtained with high polymer amount 
shows that as the polymer concentration is 
increased in fixed presence of another three 
factors it favours the formation of high drug 
loading particles. 
 
The percentage of PVA as internal phase, 
however, had a negative effect on the drug 
loading of microparticles. 
 
3D plot generated using Equation 4 is presented 
in Fig. 3. The 3D plot indicated the percent of 
surfactant and aqueous phase volume interaction 
on the drug entrapment efficiency. 
Table 3:- Analysis of variance for a 24 Factorial 
design experiment for evaluation of some variables 
effect on the furosemide  loaing in PLGA 
microparticles. 
 
 
Normal plot of residuals clearly showed that the 
variables influencing entrapment efficiency lie far 
away from the center (Fig. 4). 
 
 
Figure 4. 
 
Variables sum of squares df 
 
F 
value 
 
Prob>F 
A 
B 
C 
BC 
BD 
ABD 
BCD 
797.92 
46.34 
422.2 
32.58 
278.64 
65.49 
116.48 
1 
1 
1 
1 
1 
1 
1 
85.88 
4.99 
45.44 
3.51 
29.99 
7.05 
12.54 
0.0001 
0.0560 
0.0001 
0.0980 
0.0006 
0.0290 
0.0076 
Std. Dev. 
Mean 
C.V. 
PRESS 
3.05 
39.99 
7.62 
297.31 
R-Squared                     
0.9595 
Adj R-Squared                 
0.9240 
Pred R-Squared                 
0.8379 
Adeq Precision                 
17.280 
 
Figure 3.
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Perturbation plot is shown in Fig. 5.  This plot 
compares the effect of all the factors at a 
particular point in the design space.  
 
Based on the results and mathematical models the 
software offered optimum setting of formulation 
as shown in Table 4.  
 
Table 4:- Factorial design optimized formulation. 
Each formulation was performed three times and 
means drug loading values were recorded. 
 
The calculated desirability factor for offered 
formulations was 1.00 indicating suitability of the 
designed factorial model. As shown in Table 4 
the optimum formulation with highest drug 
loading was achieved by 199.38 mg of polymer, 
0.1% of emulsifier, 29.19 ml external phase and 
5.13 ml internal phase volumes.  
 
Physicochemical characterization of prepared 
microparticles 
Particle morphology 
 
Fig. 5. 
 
 
 
Fig. 6 shows the morphological characteristics of PLGA 
microparticles. The SEM photomicrographs of the 
microparticles reveal that they are spherical, nonporous, 
and uniform with a smooth surface. 
 
Size distribution 
The prepared microparticles revealed a unimodal 
size distribution. A classical size distribution 
curve of PLGA microparticles is presented in Fig. 
7.  
 
Differential scanning calorimetery (DSC) 
 
N
O A B C D 
DESIRA
- 
BILITY 
DRUG 
LOADING
(THEORI
TICAL) 
DRUG 
LOADING 
(EXPERI
MENTAL)
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
185.25 
189.91 
186.72 
179 
199.38 
187.16 
178.44 
200 
200 
200 
0.1 
0.1 
0.11 
0.1 
0.1 
0.1 
0.1 
0.14 
0.14 
0.15 
5.28 
5.77 
5.02 
5.01 
5.13 
5.45 
5.19 
5 
5 
5 
29.73 
29.97 
29.86 
29.51 
29.19 
29.71 
29.84 
27.13 
27.07 
26.87 
1 
1 
1 
1 
1 
1 
1 
0.797 
0.794 
0.79 
60 
60 
60 
60 
60 
60 
60 
52.5 
52.4 
52.2 
45±3.54 
52±4.5 
47±5 
40±4 
60±5 
50±3.23 
57±5 
45±3 
45±5 
43±5 
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Figure 7. 
 
The graphs of DSC were shown in Fig. 8. As 
demonstrated in the graphs (a) and (b), 
furosemide exhibited a characteristic, sharp 
exothermic peak at 220 ºC which is associated 
with the melting point of the drug and indicates 
the crystalline nature of the drug and the PLGA 
polymer had a peak at 45 ºC.  From the graph (c) 
we can find easily that the physical mixture of 
drug with carrier material had two peaks at 220 
ºC and 50 ºC respectively. These results indicated 
that their properties were kept in physical 
mixture. According to the graph (d), the peak 
which represents the properties of drug 
disappeared. The reason should be explained that 
the microparticles were formed and the drug 
crystal structure changed to amorphous state. 
 
 
Figure-8 
In vitro drug release 
The drug release is another important goal for 
microparticle formulation. The amount of 
furosemide released from microparticles during 
24 hr was evaluated using a dialysis technique. 
Dialysis membrane with a molecular weight cut-
off of 12,000 Da (Sigma) was fixed on Franz 
diffusion cell and donor and acceptor medium 
were PBS (pH 7.4), SIF (pH 7.4) and SGF (pH 
1.2). 
 
Fig. 9 showed the release behavior of furosemide 
from PLGA microparticles in various medium. 
Approximately, 8% of the drug was released in 
the SGF (pH 1.2) over a period of 24 hr and 60% 
in SIF (pH 7.4) and 50% in phosphate buffer (pH 
7.4).  
 
It was observed that in each three medium the 
release consisted of an initial rapid release phase, 
followed by a sustained release period for 24 
hours. It was expected because the adsorbed 
furosemide bound weakly to the surface making a 
platform value known as a burst effect (initial 
rapid release). Remained furosemide which was 
captured in the structure was released in a 
controlled fashion for 24hr. 
 
The followed delayed release may be attributed to 
diffusion of the dissolved drug within the PLGA 
core of the microparticle into the dissolution 
medium. 
 
The release data were analyzed on the basis of 
Korsmeyer- Peppas equation and Higuchi 
kinetics. The release rates k and n of each model 
were calculated by linear regression analysis 
using Microsoft Excel 2007 software. 
Coefficients of correlation (R 2) were used to 
evaluate the accuracy of the fit. The R 2, k and n 
values are given in Table 5. 
 
On calculating and comparing R2 (0.8763 and 
0.9835) values for Higuchi and Peppas kinetic 
models optimum formulation gave good fit to the 
Peppas model. Also because the release 
exponent: n is less than 0.5, the release 
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mechanism follows Fickian diffusion. Fickian 
drug release is characterized by a linear 
dependence of the released drug with the square 
root of time that is concentration dependent. The 
fundamental of diffusion is based on Fick’s laws, 
which describe the macroscopic transport of 
molecules by a concentration gradient.  
   
Table 5:- Values of R2, k, and n for optimum 
Formulation. 
 
 
Conclusion 
Together with a good toxicity profile, adequate 
biopharmaceutical /pharmacokinetic 
characteristics are essential for the clinical 
success of drug candidates. Currently, a high 
percentage of drugs with good efficacy/toxicity 
ratio fail to go through the drug discovery 
pipeline due to their low intestinal absorption. 
 
The two main causes of low oral bioavailability 
of drugs are poor solubility and low permeability 
through biological membranes. The origin of the 
biopharmaceutic classification system (BCS), 
which categorises drug molecules on the basis of 
solubility and permeability, has had a strong 
impact on drug research, development and 
regulatory approvals. This new concept has not 
only generated the need for extensive database 
regarding solubility and permeability coefficients 
of pre-existing molecules, but it has also made 
the determination of these values an imperative 
step in  the basic drug development process. Drug 
molecules with low solubility and poor 
permeability through biomembranes (Class IV 
drugs) are the most difficult to formulate in 
conventional drug delivery systems [26-29]. 
 
furosemide which most used in the treatment of 
edematous states associated with chronic heart 
failure1 is One of these potent drugs that belong 
to Class IV of BCS and has poor and low oral 
absorption due to its low solubility and low 
permeability. 
 
CHF is a major public health problem in most 
industrialized countries where the elderly 
population is rapidly increasing and is the leading 
cause of mortality in most developed countries 
[30]. 
 
It was previously reported that the oral 
bioavailability of furosemide was poor and shows 
erratic absorption and high intersubject variation 
in pharmacokinetic parameters; however the 
causes of these problems remains unclear. Low 
solubility and permeability, intestinal secretion 
by efflux pump; gastric elimination by acid 
hydrolysis may be causes of this problem [2, 4-
5]. Recently increasing attention has focused on 
formulating such therapeutic agents in 
biocompatible microparticles to enhance 
bioavailability, sustain drug release, and improve 
Stability from enzymatic degradation [6,31]. The 
aim of this work was to study the factorial effect 
of some process parameters on the 
pharmaceautical characteristics of PLGA 
microparticles containing furosemide to achieve a 
suitable carrier to improve intestinal absorption 
and subsequently oral bioavailability of drug. 
 
From the experimental results obtained with 
respect to particle size, drug loading and 
prolonged drug release, it may be concluded that 
the developed PLGA microparticles could be 
useful for oral administration of furosemide. 
Pharmacokinetic and pharmacodynamic studies 
are required to confirm the efficacy of these oral 
microparticles and its effect on clinical use of this 
potent drug. 
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 Higuchi Korsmeyer-Peppas 
R2 0.8763 0.9835 
Y 0.0762+0.508 0.4218x-1.5293 
K or n K=0.0762 n=0.42 
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